Vernon Bernardino

H.C. Wainwright & Co.

Image: Vernon Bernardino

Vernon Bernardino is an analyst in Seaport Global Securities' life sciences equity research department. His principal focus is on biotechnology, biopharmaceutical, specialty pharmaceutical and immunotherapy companies that focus on treatment of cancer, infectious diseases and cell-based therapies targeting inflammatory disorders and vascular diseases. Bernardino brings more than 10 years of experience covering life sciences companies at various financial institutions, including FBR & Co., Rodman & Renshaw, UBS and Dawson James. Earlier in his career, Bernardino was a buyside analyst at Nicholas Applegate Capital Management, and founded the strategic advisory group Oceros Advisors LP. Bernardino holds a bachelor's degree from Rutgers University and a master's degree in business administration (finance) from the University of San Diego.

Recent Articles

Biotech Seeks Approval of Synthetic Blood Vessel Graft 12/12/2023

Humacyte Inc. announced the submission of a Biologics License Application (BLA) to the FDA seeking approval for its lead product candidate Human Acellular Vessel (HAV), noted H.C. Wainwright & Co. Analyst Vernon Bernardino.

Texas Biotech Exceeds Alzheimer's Trial Enrollment Target 11/08/2023

This Texas-based biotech company's enrollment in its two pivotal Phase 3 trials evaluating lead drug candidate simufilam for Alzheimer's disease surpassed initial enrollment targets, noted H.C. Wainwright analyst Vernon Bernardino.

Recent Quotes

"ATNM was granted SME status, which provides assistance and financial support, as well as compelling commercial opportunities in the EU."

— Vernon Bernardino, FBR & Co. (8/9/16)
more >

Due to permission requirements, not all quotes are shown.